Wells Fargo Sees Psychedelics Market Hitting $11 Billion by 2035
Wells Fargo sees a booming psychedelic depression market, with new treatments challenging Spravato and creating big opportunities for biotech firms.
/ 5 items
#GHRS↓
Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
Compass Pathways Surges as BTIG Reaffirms Buy Rating and Trump’s Psychedelic Executive Order Sparks Sector Rally
BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.
Trump to Launch Federal Research on Psychedelic Drug Ibogaine for PTSD
Trump plans to boost research on ibogaine for PTSD in veterans, despite safety concerns and its illegal status in the US.
FDA Clears Path for Depression Treatment GH001 to Enter Final Testing Phase
GH Research's (GHRS) experimental depression treatment GH001 gets FDA approval to proceed with clinical trials after lifting of clinical hold, targeting 2026 Phase 3 launch.